Sanofi/Regeneron and Amgen race ahead in PCSK9 inhibitors on positive early data
This article was originally published in Scrip
Interest in inhibiting PCSK9 as a new therapeutic avenue in hypercholesterolaemia is gathering momentum on the back of promising clinical results reported this week showing reductions in LDL-cholesterol of over 70% with two potential drug offerings.
You may also be interested in...
Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.
The US Food and Drug Administration has cleared Clue as the second app with a birth control indication to reach market -- but the first company on the scene questions whether it's as effective as theirs.
US injectables specialist Akorn has begun to review strategic alternatives for its consumer health business, as the company looks at divesting some of its brands to increase financial flexibility and focus on its prescription generic and branded portfolio.